Multiple myeloma (MM) is a B cell malignancy resulting in osteolytic lesions and fractures. In
the disease state, bone healing is limited owing to increased osteoclastic and decreased …

Multiple myeloma (MM) drug resistance (DR) is a multistep transformation process based on
a powerful interplay between bone marrow stromal cells and MM cells that allows the latter …

Multiple myeloma (MM) is a tumor of terminally differentiated B cells that arises in the bone
marrow. Immune interactions appear as key determinants of MM progression. While myeloid …

Sclerostin is a potent inhibitor of osteoblastogenesis. Interestingly, newly diagnosed multiple
myeloma (MM) patients have high levels of circulating sclerostin that correlate with disease …

Background: Multiple myeloma (MM) remains an incurable cancer characterized by
accumulation of malignant plasma cells in the bone marrow (BM). The mechanism …

Bone marrow stromal cells (BMSCs) up-regulate B cell-activating factor (BAFF) in multiple
myeloma. Increasing experimental evidence has shown that microRNAs play a causal role …

Purpose: AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple
myeloma cells. This phase II study used a two-stage Simon design to determine the …

Multiple myeloma (MM) remains an incurable malignancy due, in part, to the influence of the
bone marrow microenvironment on survival and drug response. Identification of …

Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the
pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90% of …

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In
the absence of a single unifying genetic event contributing to disease manifestation, efforts …